@article{oai:soar-ir.repo.nii.ac.jp:00003917, author = {Yamada, Koichiro and Tsukahara, Tomonori and Yoshino, Kazuhisa and Kojima, Katsuhiko and Agawa, Hideyuki and Yamashita, Yuki and Amano, Yuji and Hatta, Mariko and Matsuzaki, Yasunori and Kurotori, Naoki and Wakui, Keiko and Fukushima, Yoshimitsu and Osada, Ryosuke and Shiozawa, Tanri and Sakashita, Kazuo and Koike, Kenichi and Kumaki, Satoru and Tanaka, Nobuyuki and Takeshita, Toshikazu}, journal = {Retrovirology}, month = {Sep}, note = {(c) 2009 Yamada et al; licensee BioMed Central Ltd. / This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited., Therapeutic retroviral vector integration near the oncogene LMO2 is thought to be a cause of leukemia in X-SCID gene therapy trials. However, no published studies have evaluated the frequency of vector integrations near exon 1 of the LMO2 locus. We identified a high incidence region (HIR) of vector integration using PCR techniques in the upstream region close to the LMO2 transcription start site in the TPA-Mat T cell line. The integration frequency of the HIR was one per 4.46 x 10(4) cells. This HIR was also found in Jurkat T cells but was absent from HeLa cells. Furthermore, using human cord blood-derived CD34(+) cells we identified a HIR in a similar region as the TPA-Mat T cell line. One of the X-linked severe combined immunodeficiency (X-SCID) patients that developed leukemia after gene therapy had a vector integration site in this HIR. Therefore, the descriptions of the location and the integration frequency of the HIR presented here may help us to better understand vector-induced leukemogenesis., Article, Retrovirology. 6:79 (2009)}, title = {Identification of a high incidence region for retroviral vector integration near exon 1 of the LMO2 locus}, volume = {6}, year = {2009} }